{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:39:52Z","timestamp":1793147992854,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The concept of psoriatic arthritis (PsA) prevention is gaining increased interest owing to the physical limitation, poor quality of life and low remission rates that are achieved with current therapies for PsA. The psoriasis-to-PsA transition offers a unique opportunity to identify individuals at increased risk of developing PsA and to implement preventive strategies. However, identifying individuals at increased risk of developing PsA is challenging as there is no consensus on how this population should be defined. This Consensus Statement puts forward recommended terminology from the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) for defining specific subgroups of individuals during the preclinical and early clinical phases of PsA to be used in research studies. Following a three-round Delphi process, consensus was reached for three terms and definitions: \u2018increased risk for PsA\u2019, \u2018psoriasis with asymptomatic synovio-entheseal imaging abnormalities\u2019 and \u2018psoriasis with musculoskeletal symptoms not explained by other diagnosis\u2019. These terms and their definitions will enable improved identification and standardization of study populations in clinical research. In the future, as increasing evidence emerges regarding the molecular and clinical features of the psoriasis-to-PsA continuum, these terms and definitions will be further refined and updated.<\/jats:p>","DOI":"10.1038\/s41584-021-00578-2","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T11:34:13Z","timestamp":1613561653000},"page":"238-243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study"],"prefix":"10.1038","volume":"17","author":[{"given":"Lourdes M.","family":"Perez-Chada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7119-8136","authenticated-orcid":false,"given":"Rebecca H.","family":"Haberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl F.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ritchlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihi","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose U.","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"578_CR1","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","volume":"69","author":"PJ Mease","year":"2013","unstructured":"Mease, P. J. et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics. J. Am. Acad. Dermatol. 69, 729\u2013735 (2013).","journal-title":"J. Am. Acad. Dermatol."},{"key":"578_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi, F. et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J. Am. Acad. Dermatol. 80, 251\u2013265.e219 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"578_CR3","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/art.39494","volume":"68","author":"L Eder","year":"2016","unstructured":"Eder, L. et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheumatol. 68, 915\u2013923 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"578_CR4","first-page":"680","volume":"35","author":"S Lee","year":"2010","unstructured":"Lee, S., Mendelsohn, A. & Sarnes, E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T 35, 680\u2013689 (2010).","journal-title":"P T"},{"key":"578_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T","volume":"45","author":"JA Husted","year":"2001","unstructured":"Husted, J. A., Gladman, D. D., Farewell, V. T. & Cook, R. J. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 45, 151\u2013158 (2001).","journal-title":"Arthritis Rheum."},{"key":"578_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/00128071-200506060-00005","volume":"6","author":"AB Kimball","year":"2005","unstructured":"Kimball, A. B., Jacobson, C., Weiss, S., Vreeland, M. G. & Wu, Y. The psychosocial burden of psoriasis. Am. J. Clin. Dermatol. 6, 383\u2013392 (2005).","journal-title":"Am. J. Clin. Dermatol."},{"key":"578_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/rheumatology\/keu264","volume":"54","author":"W Tillett","year":"2015","unstructured":"Tillett, W. et al. Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study. Rheumatology 54, 157\u2013162 (2015).","journal-title":"Rheumatology"},{"key":"578_CR8","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","volume":"149","author":"AW Armstrong","year":"2013","unstructured":"Armstrong, A. W., Robertson, A. D., Wu, J., Schupp, C. & Lebwohl, M. G. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003\u20132011. JAMA Dermatol. 149, 1180\u20131185 (2013).","journal-title":"JAMA Dermatol."},{"key":"578_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jaad.2015.05.001","volume":"73","author":"AP Villani","year":"2015","unstructured":"Villani, A. P. et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J. Am. Acad. Dermatol. 73, 242\u2013248 (2015).","journal-title":"J. Am. Acad. Dermatol."},{"key":"578_CR10","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1136\/ard.2011.150938","volume":"70","author":"DD Gladman","year":"2011","unstructured":"Gladman, D. D., Thavaneswaran, A., Chandran, V. & Cook, R. J. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann. Rheum. Dis. 70, 2152\u20132154 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"578_CR11","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","volume":"74","author":"M Haroon","year":"2015","unstructured":"Haroon, M., Gallagher, P. & FitzGerald, O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann. Rheum. Dis. 74, 1045\u20131050 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"578_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s11926-018-0785-6","volume":"20","author":"R Haberman","year":"2018","unstructured":"Haberman, R. et al. Bridging the gaps in the care of psoriasis and psoriatic arthritis: the role of combined clinics. Curr. Rheumatol. Rep. 20, 76 (2018).","journal-title":"Curr. Rheumatol. Rep."},{"key":"578_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","volume":"15","author":"JU Scher","year":"2019","unstructured":"Scher, J. U., Ogdie, A., Merola, J. F. & Ritchlin, C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat. Rev. Rheumatol. 15, 153\u2013166 (2019).","journal-title":"Nat. Rev. Rheumatol."},{"key":"578_CR14","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1136\/annrheumdis-2011-200990","volume":"71","author":"DM Gerlag","year":"2012","unstructured":"Gerlag, D. M. et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for risk factors for rheumatoid arthritis. Ann. Rheum. Dis. 71, 638\u2013641 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"578_CR15","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/DCR.0b013e3181a0b358","volume":"52","author":"CG Burt","year":"2009","unstructured":"Burt, C. G. et al. Developing a research agenda for the American Society of Colon and Rectal Surgeons: results of a Delphi approach. Dis. Colon Rectum 52, 898\u2013905 (2009).","journal-title":"Dis. Colon Rectum"},{"key":"578_CR16","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00256-011-1145-z","volume":"40","author":"J Steurer","year":"2011","unstructured":"Steurer, J. The Delphi method: an efficient procedure to generate knowledge. Skeletal Radiol. 40, 959\u2013961 (2011).","journal-title":"Skeletal Radiol."},{"key":"578_CR17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/ACM.0000000000001092","volume":"91","author":"J Waggoner","year":"2016","unstructured":"Waggoner, J., Carline, J. D. & Durning, S. J. Is there a consensus on consensus methodology? Descriptions and recommendations for future consensus research. Acad. Med. 91, 663\u2013668 (2016).","journal-title":"Acad. Med."},{"key":"578_CR18","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3899\/jrheum.181094","volume":"46","author":"S Humphrey-Murto","year":"2019","unstructured":"Humphrey-Murto, S. et al. Consensus building in OMERACT: recommendations for use of the Delphi for core outcome set development. J. Rheumatol. 46, 1041\u20131046 (2019).","journal-title":"J. Rheumatol."},{"key":"578_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1177\/2475530320913879","volume":"5","author":"R Haberman","year":"2020","unstructured":"Haberman, R. et al. Psoriasis and psoriatic arthritis clinics multicenter advancement network consortium (PPACMAN) 2018 Annual Meeting summary. J. Psoriasis Psoriatic Arthritis 5, 68\u201372 (2020).","journal-title":"J. Psoriasis Psoriatic Arthritis"},{"key":"578_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris, P. A. et al. Research electronic data capture (REDCap) \u2014 a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42, 377\u2013381 (2009).","journal-title":"J. Biomed. Inform."},{"key":"578_CR21","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/art.39973","volume":"69","author":"L Eder","year":"2017","unstructured":"Eder, L. et al. The development of psoriatic arthritis in patients with psoriasis is preceded by a period of nonspecific musculoskeletal symptoms: a prospective cohort study. Arthritis Rheumatol. 69, 622\u2013629 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"578_CR22","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor, W. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 54, 2665\u20132673 (2006).","journal-title":"Arthritis Rheum."},{"key":"578_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.crad.2012.07.018","volume":"68","author":"L Eder","year":"2013","unstructured":"Eder, L., Barzilai, M., Peled, N., Gladman, D. D. & Zisman, D. The use of ultrasound for the assessment of enthesitis in patients with spondyloarthritis. Clin. Radiol. 68, 219\u2013223 (2013).","journal-title":"Clin. Radiol."},{"key":"578_CR24","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.berh.2010.05.003","volume":"24","author":"MA D\u2019Agostino","year":"2010","unstructured":"D\u2019Agostino, M. A. Ultrasound imaging in spondyloarthropathies. Best Pract. Res. Clin. Rheumatol. 24, 693\u2013700 (2010).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"578_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3899\/jrheum.171466","volume":"46","author":"O Elalouf","year":"2019","unstructured":"Elalouf, O. et al. Psoriatic arthritis sonographic enthesitis instruments: a systematic review of the literature. J. Rheumatol. 46, 43\u201356 (2019).","journal-title":"J. Rheumatol."},{"key":"578_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/art.41239","author":"D Simon","year":"2020","unstructured":"Simon, D. et al. Structural entheseal lesions in patients with psoriasis are associated with an increased risk of progression to psoriatic arthritis. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41239 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"578_CR27","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/art.40778","volume":"71","author":"L Savage","year":"2019","unstructured":"Savage, L. et al. Regression of peripheral subclinical enthesopathy in therapy-naive patients treated with ustekinumab for moderate-to-severe chronic plaque psoriasis: a fifty-two-week, prospective, open-label feasibility study. Arthritis Rheumatol. 71, 626\u2013631 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"578_CR28","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","volume":"48","author":"EG Araujo","year":"2019","unstructured":"Araujo, E. G. et al. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin. Arthritis Rheum. 48, 632\u2013637 (2019).","journal-title":"Semin. Arthritis Rheum."},{"key":"578_CR29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13075-019-1957-0","volume":"21","author":"E Kampylafka","year":"2019","unstructured":"Kampylafka, E. et al. Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study. Arthritis Res. Ther. 21, 178 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"578_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24146","author":"L Eder","year":"2020","unstructured":"Eder, L. et al. Health care utilization for musculoskeletal issues during the pre-diagnosis period in psoriatic arthritis \u2014 a population-based study. Arthritis Care Res. https:\/\/doi.org\/10.1002\/acr.24146 (2020).","journal-title":"Arthritis Care Res."},{"key":"578_CR31","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester, G. R. et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 391, 2503\u20132512 (2018).","journal-title":"Lancet"},{"key":"578_CR32","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/art.40061","volume":"69","author":"KD Deane","year":"2017","unstructured":"Deane, K. D., Striebich, C. C. & Holers, V. M. Prevention of rheumatoid arthritis: now is the time, but how to proceed? Arthritis Rheumatol. 69, 873\u2013877 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"578_CR33","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/annrheumdis-2017-212763","volume":"78","author":"DM Gerlag","year":"2019","unstructured":"Gerlag, D. M. et al. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Ann. Rheum. Dis. 78, 179\u2013185 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"578_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3403-7","volume":"20","author":"M Al-Laith","year":"2019","unstructured":"Al-Laith, M. et al. Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. Trials 20, 429 (2019).","journal-title":"Trials"},{"key":"578_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-018-3076-7","volume":"19","author":"NJ Olsen","year":"2018","unstructured":"Olsen, N. J. et al. Study of anti-malarials in incomplete lupus erythematosus (SMILE): study protocol for a randomized controlled trial. Trials 19, 694 (2018).","journal-title":"Trials"},{"key":"578_CR36","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02603146 (2021)."},{"key":"578_CR37","doi-asserted-by":"publisher","first-page":"102506","DOI":"10.1016\/j.autrev.2020.102506","volume":"19","author":"M Mahler","year":"2020","unstructured":"Mahler, M., Martinez-Prat, L., Sparks, J. A. & Deane, K. D. Precision medicine in the care of rheumatoid arthritis: focus on prediction and prevention of future clinically-apparent disease. Autoimmun. Rev. 19, 102506 (2020).","journal-title":"Autoimmun. Rev."},{"key":"578_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11926-019-0876-z","volume":"21","author":"C Ritchlin","year":"2019","unstructured":"Ritchlin, C. & Scher, J. U. Strategies to improve outcomes in psoriatic arthritis. Curr. Rheumatol. Rep. 21, 72 (2019).","journal-title":"Curr. Rheumatol. Rep."},{"key":"578_CR39","first-page":"ii14","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman, D. D., Antoni, C., Mease, P., Clegg, D. O. & Nash, P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis. 64, ii14\u201317 (2005).","journal-title":"Ann. Rheum. Dis."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41584-021-00578-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-021-00578-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-021-00578-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:22:39Z","timestamp":1684606959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-021-00578-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["578"],"URL":"https:\/\/doi.org\/10.1038\/s41584-021-00578-2","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"20 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.H.H. declares they have received consultation honoraria from Janssen. V.C. declares they have received research grants and\/or advisory board honoraria from AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB. V.C. also declares that their spouse is employed by Eli Lilly. C.F.R. declares they have received consultation and\/or investigator honoraria from AbbVie, Eli Lilly and Novartis. L.E. declares they have received consultation honoraria and non-restricted research and educational grants from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB. P.M. declares they have received research grants, consultation and\/or speaker honoraria from AbbVie, Amgen, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, Sun Pharma and UCB. S.R. declares they have received consultation honoraria from Amgen, Janssen, Novartis and Pfizer and have been involved in clinical trials with Amgen and Celgene. A.O. declares they have received consultation honoraria from AbbVie, Amgen, BMS, Celgene, Corrona, Eli Lilly, Janssen, Novartis and Pfizer and have received grant support from Amgen (to Forward\/National Databank for Rheumatic Disease) and from Novartis and Pfizer (to the University of Pennsylvania). J.F.M. declares they have received consultation and\/or investigator honoraria from AbbVie, Arena, Avotres, Biogen, Celgene, Dermavant, Eli Lilly, EMD Sorono, Janssen, Leo Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma and UCB. J.U.S. declares they have received consultation and\/or investigator honoraria from AbbVie, Janssen, Novartis, Pfizer, Sanofi and UCB. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}